Rapid and Cost Effective In Vivo Evaluation of Human Specific Biological Therapies
Assessing human biological therapeutics requires specific preclinical models, featuring a range of human targets. We provide a panel of humanized drug target models expressing human immune checkpoints such as PD-1, PD-L1, and CTLA-4.
Our HuGEMM™ models allow the evaluation of specific human biological therapies in vivo, in mice with a fully functional murine immune system. Each model features a humanized drug target, with knock-in of a human target protein directly replacing its murine counterpart.
Humanized drug target models overcome species specificity issues of syngeneic models (which can only be used for surrogate anti-mouse checkpoint inhibitor testing), and are more cost-effective and rapid than fully humanized systems.
Currently available human single target knock-in models include: PD-1, PD-L1, CTLA-4, OX40, CD137, CD40, LAG3, and CD3E (transgenic), with double knock-in combination models also developed.
Mouse tumor cells engineered to express humanized targets (HuCELL™ models) are also available for key proteins such as PD-L1.
Fully Validated Models for Client Data Confidence
All of our HuGEMM and HuCELL models are well-characterized with target expression validation, immunotherapy benchmarking, and immunoprofiling data, providing assurance to your research needs.
Contact us today for further information and for expert assistance in selecting the right murine immuno-oncology models for your preclinical research needs.